These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35774732)

  • 1. Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing.
    Nogueira Costa I; Reis J; Meireles S; Ribeiro MJ; Barbosa M; Augusto I
    Eur J Case Rep Intern Med; 2022; 9(5):003331. PubMed ID: 35774732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
    BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective.
    Matsumoto T; Shiota M; Blas L; Eto M
    Cancer Manag Res; 2022; 14():2389-2397. PubMed ID: 35967752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
    J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-Gene Next-Generation Sequencing Panel for Analysis of
    Maloberti T; De Leo A; Coluccelli S; Sanza V; Gruppioni E; Altimari A; Zagnoni S; Giunchi F; Vasuri F; Fiorentino M; Mollica V; Ferrari S; Miccoli S; Visani M; Turchetti D; Massari F; Tallini G; de Biase D
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
    Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
    Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
    Slootbeek PHJ; Tolmeijer SH; Mehra N; Schalken JA
    Crit Rev Clin Lab Sci; 2024 May; 61(3):178-204. PubMed ID: 37882463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-emergent neuroendocrine prostate cancer with a germline
    Pandya D; Shah M; Kaplan F; Martino C; Levy G; Kazanjian M; Batter S; Martignetti J; Frank RC
    Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib for the treatment of metastatic prostate cancer.
    Dror CM; Wyatt AW; Chi KN
    Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
    Catalano M; Lapucci A; Nobili S; De Gennaro Aquino I; Vascotto IA; Antonuzzo L; Villari D; Nesi G; Mini E; Roviello G
    Cancer Chemother Pharmacol; 2024 Jan; 93(1):1-9. PubMed ID: 37934252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.
    LeVee A; Lin CY; Posadas E; Figlin R; Bhowmick NA; Di Vizio D; Ellis L; Rosser CJ; Freeman MR; Theodorescu D; Freedland SJ; Gong J
    Onco Targets Ther; 2021; 14():4819-4832. PubMed ID: 34552338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in
    Carneiro BA; Collier KA; Nagy RJ; Pamarthy S; Sagar V; Fairclough S; Odegaard J; Lanman RB; Costa R; Taxter T; Kuzel TM; Fan A; Chae YK; Cristofanilli M; Hussain MH; Abdulkadir SA; Giles FJ
    JCO Precis Oncol; 2018; 2():. PubMed ID: 31501807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations.
    Teply BA; Antonarakis ES
    Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1293-1304. PubMed ID: 36285641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Fujimoto N; Harada K; Shiota M; Tomisaki I; Minato A; Nagata Y; Kimuro R; Harada M; Fujisawa M
    Anticancer Res; 2021 Oct; 41(10):4687-4695. PubMed ID: 34593416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M
    N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.
    Coquan E; Penel N; Lequesne J; Leman R; Lavaud P; Neviere Z; Brachet PE; Meriaux E; Carnot A; Boutrois J; Castera M; Goardon N; Muller E; Leconte A; Thiery-Vuillemin A; Clarisse B; Joly F
    Ther Adv Urol; 2024; 16():17562872241229876. PubMed ID: 38425504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of the PARP Inhibitor in
    Inoue T; Sekito S; Kageyama T; Sugino Y; Sasaki T
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.